Recognition of potential predictive markers for diagnosis in Korean serous ovarian cancer patients at stage IIIc using array comparative genomic hybridization with high resolution

Molecular and Cellular Toxicology

Volumn 7, Issue 1, 2011, Pages 77-86

  Kwon, Jee Young ^a,b   Seo, Young Rok ^a,b   Ahn, Woong Shick ^c  

^a Dongguk University   (South Korea)

^b Kyung Hee University   (South Korea)

^c The Catholic University of Korea   (South Korea)

Author keywords

Array comparative genomic hybridization (array CGH); Copy number variations; Serous ovarian Cancer

Indexed keywords

EID: 79960097842     PISSN: 1738642X     EISSN: 20928467     Source Type: Journal    
DOI: 10.1007/s13273-011-0011-3     Document Type: Article

References (38)

1. McGuire ,W. P. 3rd & Markman, M. Primary ovarian cancer chemotherapy: current standards of care. Br J Cancer 3:3S-8S (2003).
2. Heintz, A. P. et al. Carcinoma of the ovary. Int J Gynaecol Obstet 1:135-166 (2003). (Pubitemid 39658498)
3. Piccart, M. et al. Randomized intergroup trial of cisplatin- paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 92:699-708 (2000). (Pubitemid 30365530)
4. Kim, G. J. et al. Detection of genetic alterations in Korean ovarian carcinomas by degenerate oligonucleotide primed polymerase chain reaction-comparative genomic hybridization. Cancer Genet Cytogenet 147: 23-27 (2003).
5. Kim, H. S. et al. Genetic polymorphisms affecting clinical outcomes in epithelial ovarian cancer patients treated with taxanes and platinum compounds: A Korean population-based study. Gynecologic Oncology 113:264-269 (2009).
6. Hiorns, L. R. et al. Variation in RNA expression and genomic DNA content acquired during cell culture. Br J Cancer 90:476-482 (2004). (Pubitemid 38250648)
7. Telenius, H. et al. Degenerate oligonucleotide-primed PCR: general amplification of target DNA by a single degenerate primer. Genomics 13:718-725 (1992).
8. Mantripragada, K. K., Buckley, P. G., de Stahl, T. D. & Dumanski, J. P. Genomic microarrays in the spotlight. Trends Genet 20:87-94 (2004). (Pubitemid 38121360)
9. Squire, J. A. et al. Molecular cytogenetic analysis of head and neck squamous cell carcinoma: by comparative genomic hybridization, spectral karyotyping, and expression array analysis. Head Neck 24:874-887 (2002).
10. Heiskanen, M. et al. CGH, cDNA and tissue microarray analyses implicate FGFR2 amplification in a small subset of breast tumors. Anal Cell Pathol 22:229-234 (2001). (Pubitemid 32960014)
11. Prasad, M. et al. High definition cytogenetics and oligonucleotide aCGH analyses of cisplatin-resistant ovarian cancer cells. Genes Chromosomes Cancer 47:427-436 (2008). (Pubitemid 351451797)
12. Staebler, A. et al. Chromosomal losses of regions on 5q and lack of high-level amplifications at 8q24 are associated with favorable prognosis for ovarian serous carcinoma. Genes Chromosomes Cancer 45:905-917 (2006). (Pubitemid 44360178)
13. Kim, S. W. et al. Analysis of chromosomal changes in serous ovarian carcinoma using high-resolution array comparative genomic hybridization: Potential predictive markers of chemoresistant disease. Genes Chromosomes Cancer 46:1-9 (2007). (Pubitemid 44772867)
14. Bernardini, M. et al. High-resolution mapping of genomic imbalance and identification of gene expression profiles associated with differential chemotherapy response in serous epithelial ovarian cancer. Neoplasia 7:603-613 (2005). (Pubitemid 40967761)
15. Osterberg, L., Levan, K., Partheen, K., Helou, K. & Horvath, G. Cytogenetic analysis of carboplatin resistancein early-stage epithelial ovarian carcinoma. Cancer Genet Cytogenet 163:144-150 (2005). (Pubitemid 41758456)
16. Suzuki, S. et al. An approach to analysis of large-scale correlations between genome changes and clinical endpoints in ovarian cancer. Cancer Res 60:5382-5385 (2000).
17. Birrer, M. J. et al. Whole genome oligonucleotidebased array comparative genomic hybridization analysis identified fibroblast growth factor 1 as a prognostic marker for advanced-stage serous ovarian adenocarcinomas. J Clin Oncol 25:2281-2287 (2007). (Pubitemid 46954656)
18. Nanjundan, M. et al. Amplification of MDS1/EVI1 and EVI1, located in the 3q26.2 amplicon, is associated with favorable patient prognosis in ovarian cancer. Cancer Res 67:3074-3084 (2007). (Pubitemid 46724844)
19. Mayr, D. et al. Analysis of gene amplification and prognostic markers in ovarian cancer using comparative genomic hybridization for microarrays and immunohistochemical analysis for tissue microarrays. Am J Clin Pathol 126:101-109 (2006). (Pubitemid 44025077)
20. Farley, J. et al. Cyclin E expression is a significant predictor of survival in advanced, sub optimally debulked ovarian epithelial cancers: a Gynecologic Oncology Group study. Cancer Res 63:1235-1241 (2003). (Pubitemid 36348700)
21. Nakao, K. et al. High-resolution analysis of DNA copy number alterations in colorectal cancer by array-based comparative genomic hybridization. Carcinogenesis 25:1345-1357 (2004). (Pubitemid 39162701)
22. Tabarés-Seisdedos, R. & Rubenstein, J. L. Chromosome 8p as a potential hub for developmental neuropsychiatric disorders: implications for schizophrenia, autism and cancer. Mol Psychiatry 14:563-589 (2009).
23. Turner, N. et al. Intergrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets. Oncogene 29:2013-2023 (2010).
24. Desprez, P. Y., Sumida, T. & Coppe, J. P. Helix-loop-helix proteins in mammary gland development and breast cancer. J Mammary Gland Biol Neoplasia 8:225-239 (2003). (Pubitemid 38129944)
25. Norton, J. D. ID helix-loop-helix proteins in cell growth, differentiation and tumorigenesis. J Cell Sci 113:3897-3902 (2000).
26. Noetzel, E. et al. Promoter methylation-associated loss of ID4 expression is a marker of tumour recurrence in human breast cancer. BMC Cancer 8:154 (2008).
27. Beger, C. et al. Identification of Id4 as a regulator of BRCA1 expression by using a ribozyme-library-based inverse genomics approach. PNAS 98:130-135 (2001). (Pubitemid 32095875)
28. Douglas, L. F. Neuregulins: functions, forms, and signaling strategies. Exp Cell Res 284: 14-30 (2003).
29. Chua, Y. L. et al. The NRG1 gene is frequently silenced by methylation in breast cancers and is a strong candidate for the 8p tumour suppressor gene. Oncogene 28:4041-4052 (2009).
30. Pole, J. C. et al. High-resolution analysis of chromosome rearrangements on 8p in breast, colon and pancreatic cancer reveals a complex pattern of loss, gain and translocation. Oncogene 25:5693-5706 (2006). (Pubitemid 44387624)
31. Prentice, L. M. et al. NRG1 gene rearrangements in clinical breast cancer: identification of an adjacent novel amplicon associated with poor prognosis. Oncogene 24:7281-7289 (2005). (Pubitemid 41622232)
32. Owens, D. M. & Keyse, S. M. Differential regulation of MAP kinase signalling by dual-specificity proteinphosphatases. Oncogene 26:3203-3213 (2007). (Pubitemid 46763015)
33. Yip-Schneider, M. T. et al. Pancreatic tumor cells with mutant K-ras suppress ERK activity by MEKdependent induction of MAP kinase phosphatase-2. Biochem Biophys Res Commun 280:992-997 (2001). (Pubitemid 32924437)
34. Sieben, N. L. et al. Differential gene expression in ovarian tumors reveals Dusp 4 and Serpina 5 as key regulators for benign behavior of serous borderline tumors. J Clin Oncol 23:7257-7264 (2005). (Pubitemid 46202340)
35. Venter, D. J. et al. Complex CGH alterations on chromosome arm 8p at candidate tumor suppressor gene loci in breast cancer cell lines. Cancer Genet Gytogenet 160:134-140 (2005). (Pubitemid 40910048)
36. Wang, Y. et al. Gene-expression profiles to predict distant metastasis of lymph node negative primary breast cancer. Lancet 365:671-678 (2005).
37. Rosell, R., Taron, M., Camps, C. & López-Vivanco, G. Influence of genetic markers on survival in non-small cell lung cancer. Drugs Today (Barc) 39:775-786 (2003). (Pubitemid 37500404)
38. Ferrandina, G. et al. Expression of nucleoside transporters, deoxycitidine kinase, ribonucleotide reductase regulatory subunits, and gemcitabine catabolic enzymes in primary ovarian cancer. Cancer Chemother Pharmacol 65:679-686 (2010).